Unnamed: 0
int64 0
1.41M
| headline
stringlengths 3
513
| url
stringlengths 33
162
| publisher
stringlengths 3
46
| date
timestamp[s] | stock
stringlengths 1
5
|
|---|---|---|---|---|---|
1,412,121 | Zoetis shares are trading lower. Not seeing any news to justify the price action. | https://www.benzinga.com/markets/wiim/19/10/14639555/zoetis-shares-are-trading-lower-not-seeing-any-news-to-justify-the-price-action | Benzinga Newsdesk | 2019-10-22T00:00:00 | ZTS |
1,412,122 | The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch | https://www.benzinga.com/general/biotech/19/10/14600857/the-daily-biotech-pulse-akebia-sues-cms-roche-raises-guidance-yet-again-titan-medical-entangled-i | Shanthi Rexaline | 2019-10-16T00:00:00 | ZTS |
1,412,123 | Stocks That Hit 52-Week Highs On Tuesday | https://www.benzinga.com/news/19/10/14595399/stocks-that-hit-52-week-highs-on-tuesday | Lisa Levin | 2019-10-15T00:00:00 | ZTS |
1,412,124 | Zoetis Reports CEO Juan Ramon Alaix To Retire; Kristin Peck Named Successor | https://www.benzinga.com/news/19/10/14537183/zoetis-reports-ceo-juan-ramon-alaix-to-retire-kristin-peck-named-successor | Benzinga Newsdesk | 2019-10-03T00:00:00 | ZTS |
1,412,125 | Shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak ADP jobs report. There is also uncertainty in the market over the upcoming U.S.-China meeting next week. | https://www.benzinga.com/markets/wiim/19/10/14530664/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-on-cont | Benzinga Newsdesk | 2019-10-02T00:00:00 | ZTS |
1,412,126 | Morgan Stanley Maintains Equal-Weight on Zoetis, Raises Price Target to $136 | https://www.benzinga.com/news/19/09/14512025/morgan-stanley-maintains-equal-weight-on-zoetis-raises-price-target-to-136 | Vick Meyer | 2019-09-30T00:00:00 | ZTS |
1,412,127 | Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival. | https://www.benzinga.com/markets/wiim/19/09/14466308/shares-of-several-drug-companies-are-trading-higher-after-senate-majority-leader-mcconnell-suggested | Benzinga Newsdesk | 2019-09-20T00:00:00 | ZTS |
1,412,128 | European Commission Grants Marketing Authorization To Simparica Trio, A Once-Monthly Triple Combination Antiparasitic Medication for Dogs | https://www.benzinga.com/general/biotech/19/09/14464298/european-commission-grants-marketing-authorization-to-simparica-trio-a-once-monthly-triple-combin | Benzinga Newsdesk | 2019-09-20T00:00:00 | ZTS |
1,412,129 | Shares of several drugmakers are trading lower on news of a drug pricing bill being developed by House Democrats. The proposed bill would set US drug prices based on prices in other wealthy countries. | https://www.benzinga.com/markets/wiim/19/09/14407152/shares-of-several-drugmakers-are-trading-lower-on-news-of-a-drug-pricing-bill-being-developed-by-hou | Benzinga Newsdesk | 2019-09-10T00:00:00 | ZTS |
1,412,130 | The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris | https://www.benzinga.com/general/biotech/19/09/14403465/the-daily-biotech-pulse-translate-bio-halts-mrna-therapy-trial-roche-multiple-sclerosis-biomarker | Shanthi Rexaline | 2019-09-10T00:00:00 | ZTS |
1,412,131 | Zoetis Scientists Present Positive Efficacy Data for Investigational Triple Combination Parasiticide at American Heartworm Society Meeting | https://www.benzinga.com/general/biotech/19/09/14400657/zoetis-scientists-present-positive-efficacy-data-for-investigational-triple-combination-parasitic | Benzinga Newsdesk | 2019-09-09T00:00:00 | ZTS |
1,412,132 | The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine | https://www.benzinga.com/general/biotech/19/08/14296435/the-daily-biotech-pulse-fda-likes-nabrivas-antibiotic-snubs-sareptas-dmd-drug-moderna-gets-fast-t | Shanthi Rexaline | 2019-08-20T00:00:00 | ZTS |
1,412,133 | Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war. | https://www.benzinga.com/markets/wiim/19/08/14293088/shares-of-several-healthcare-companies-are-trading-higher-as-optimism-increased-for-a-resolution-to | Benzinga Newsdesk | 2019-08-19T00:00:00 | ZTS |
1,412,134 | Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal. | https://www.benzinga.com/markets/wiim/19/08/14285917/shares-of-healthcare-companies-are-trading-higher-as-us-markets-rebound-from-recent-weakness-followi | Benzinga Newsdesk | 2019-08-16T00:00:00 | ZTS |
1,412,135 | Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products. | https://www.benzinga.com/markets/wiim/19/08/14257980/shares-of-several-healthcare-companies-are-trading-higher-with-the-overall-market-after-the-u-s-anno | Benzinga Newsdesk | 2019-08-13T00:00:00 | ZTS |
1,412,136 | SunTrust Robinson Humphrey Maintains Hold on Zoetis, Raises Price Target to $130 | https://www.benzinga.com/news/19/08/14255561/suntrust-robinson-humphrey-maintains-hold-on-zoetis-raises-price-target-to-130 | Vick Meyer | 2019-08-13T00:00:00 | ZTS |
1,412,137 | A List Of Stocks Reaching New 52-Week Highs | https://www.benzinga.com/news/19/08/14240421/a-list-of-stocks-reaching-new-52-week-highs | Lisa Levin | 2019-08-09T00:00:00 | ZTS |
1,412,138 | The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2 | https://www.benzinga.com/general/biotech/19/08/14237665/the-daily-biotech-pulse-vascepa-delay-sends-amarin-reeling-eidos-jumps-on-buyout-offer-nektars-bi | Shanthi Rexaline | 2019-08-09T00:00:00 | ZTS |
1,412,139 | Stocks That Set New 52-Week Highs Thursday | https://www.benzinga.com/news/19/08/14232278/stocks-that-set-new-52-week-highs-thursday | Lisa Levin | 2019-08-08T00:00:00 | ZTS |
1,412,140 | The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout | https://www.benzinga.com/general/biotech/19/08/14216922/the-daily-biotech-pulse-novartis-stands-by-zolgensma-gw-pharma-q2-propelled-by-epidiolex-sales-io | Shanthi Rexaline | 2019-08-07T00:00:00 | ZTS |
1,412,141 | 85 Biggest Movers From Yesterday | https://www.benzinga.com/news/19/08/14216966/85-biggest-movers-from-yesterday | Lisa Levin | 2019-08-07T00:00:00 | ZTS |
1,412,142 | 68 Stocks Moving In Tuesday's Mid-Day Session | https://www.benzinga.com/news/19/08/14212092/68-stocks-moving-in-tuesdays-mid-day-session | Lisa Levin | 2019-08-06T00:00:00 | ZTS |
1,412,143 | New 52-Week-High Achievers For Tuesday Morning | https://www.benzinga.com/news/19/08/14210274/new-52-week-high-achievers-for-tuesday-morning | Lisa Levin | 2019-08-06T00:00:00 | ZTS |
1,412,144 | Zoetis shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The company also raised FY19 EPS and sales guidance. | https://www.benzinga.com/markets/wiim/19/08/14209766/zoetis-shares-are-trading-higher-after-the-company-reported-better-than-expected-q2-eps-and-sales-re | Benzinga Newsdesk | 2019-08-06T00:00:00 | ZTS |
1,412,145 | Zoetis Reports Q2 Earnings Beat, Raises Guidance | https://www.benzinga.com/news/earnings/19/08/14208556/zoetis-reports-q2-earnings-beat-raises-guidance | Tanzeel Akhtar | 2019-08-06T00:00:00 | ZTS |
1,412,146 | The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering | https://www.benzinga.com/general/biotech/19/08/14206788/the-daily-biotech-pulse-sanofis-dupixent-found-effective-for-pediatric-itchy-skin-novavax-gets-no | Shanthi Rexaline | 2019-08-06T00:00:00 | ZTS |
1,412,147 | Zoetis Raises FY19 Guidance: Adj. EPS From $3.42-$3.52 To $3.53-$3.60 vs $3.49 Estimate, Sales From $6.1B-$6.225B To $6.175B-$6.275B vs $6.19B Est. | https://www.benzinga.com/news/19/08/14207736/zoetis-raises-fy19-guidance-adj-eps-from-3-42-3-52-to-3-53-3-60-vs-3-49-estimate-sales-from-6-1b-6-2 | Benzinga Newsdesk | 2019-08-06T00:00:00 | ZTS |
1,412,148 | Zoetis Q2 Adj. EPS $0.9 Beats $0.82 Estimate, Sales $1.547B Beat $1.52B Estimate | https://www.benzinga.com/news/earnings/19/08/14207729/zoetis-q2-adj-eps-0-9-beats-0-82-estimate-sales-1-547b-beat-1-52b-estimate | Benzinga Newsdesk | 2019-08-06T00:00:00 | ZTS |
1,412,149 | Earnings Scheduled For August 6, 2019 | https://www.benzinga.com/news/earnings/19/08/14206548/earnings-scheduled-for-august-6-2019 | Lisa Levin | 2019-08-06T00:00:00 | ZTS |
1,412,150 | Shares of several drug/pharma/medical equipment companies trading lower given weakness in broader stock market following concerns with China trade tensions. | https://www.benzinga.com/markets/wiim/19/08/14202009/shares-of-several-drugpharma-companies-trading-lower-given-weakness-in-broader-stock-market-followin | Benzinga Newsdesk | 2019-08-05T00:00:00 | ZTS |
1,412,151 | Zoetis Will Acquire Platinum Performance | https://www.benzinga.com/m-a/19/07/14111237/zoetis-will-acquire-platinum-performance | Tanzeel Akhtar | 2019-07-22T00:00:00 | ZTS |
1,412,152 | Stifel Nicolaus Maintains Buy on Zoetis, Raises Price Target to $130 | https://www.benzinga.com/news/19/07/14109390/stifel-nicolaus-maintains-buy-on-zoetis-raises-price-target-to-130 | Vick Meyer | 2019-07-22T00:00:00 | ZTS |
1,412,153 | Zoetis To Acquire Platinum Performance, A Leading Nutrition-Focused Animal Health Business For Equine And Petcare Markets | https://www.benzinga.com/m-a/19/07/14108716/zoetis-to-acquire-platinum-performance-a-leading-nutrition-focused-animal-health-business-for-equine | Benzinga Newsdesk | 2019-07-22T00:00:00 | ZTS |
1,412,154 | Zoetis to Acquires Platinum Performance, Terms Not Disclosed | https://www.benzinga.com/m-a/19/07/14108702/zoetis-to-acquires-platinum-performance-terms-not-disclosed | Benzinga Newsdesk | 2019-07-22T00:00:00 | ZTS |
1,412,155 | BofA Downgrades Veterinary Medicine Maker Zoetis On Valuation | https://www.benzinga.com/analyst-ratings/analyst-color/19/07/14009549/bofa-downgrades-veterinary-medicine-maker-zoetis-on-valuation | Priya Nigam | 2019-07-01T00:00:00 | ZTS |
1,412,156 | 10 Biggest Price Target Changes For Monday | https://www.benzinga.com/analyst-ratings/price-target/19/07/14009745/10-biggest-price-target-changes-for-monday | Lisa Levin | 2019-07-01T00:00:00 | ZTS |
1,412,157 | Benzinga's Top Upgrades, Downgrades For July 1, 2019 | https://www.benzinga.com/analyst-ratings/upgrades/19/07/14009507/benzingas-top-upgrades-downgrades-for-july-1-2019 | Lisa Levin | 2019-07-01T00:00:00 | ZTS |
1,412,158 | Bank of America Downgrades Zoetis to Neutral, Raises Price Target to $120 | https://www.benzinga.com/news/19/07/14008332/bank-of-america-downgrades-zoetis-to-neutral-raises-price-target-to-120 | Benzinga_Newsdesk | 2019-07-01T00:00:00 | ZTS |
1,412,159 | The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge | https://www.benzinga.com/general/biotech/19/06/13948279/the-daily-biotech-pulse-diamedica-reports-positive-data-for-chronic-kidney-disease-drug-eloxx-off | Shanthi Rexaline | 2019-06-20T00:00:00 | ZTS |
1,412,160 | The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut | https://www.benzinga.com/general/biotech/19/06/13941625/the-daily-biotech-pulse-positive-readouts-from-adamas-and-ironwood-sesen-bio-to-offer-shares-stok | Shanthi Rexaline | 2019-06-19T00:00:00 | ZTS |
1,412,161 | Barclays Initiates Coverage On Zoetis with Overweight Rating, Announces $120 Price Target | https://www.benzinga.com/news/19/06/13900667/barclays-initiates-coverage-on-zoetis-with-overweight-rating-announces-120-price-target | Vick Meyer | 2019-06-11T00:00:00 | ZTS |
1,412,162 | The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering | https://www.benzinga.com/general/biotech/19/06/13872351/the-daily-biotech-pulse-takeda-pulls-plug-on-amyloidosis-drug-trial-chiasma-preps-for-drug-launch | Shanthi Rexaline | 2019-06-06T00:00:00 | ZTS |
1,412,163 | The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache | https://www.benzinga.com/general/biotech/19/06/13864534/the-daily-biotech-pulse-curtains-down-on-asco-rewalk-flies-eli-lillys-migraine-drug-approved-for- | Shanthi Rexaline | 2019-06-05T00:00:00 | ZTS |
1,412,164 | Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook. | https://www.benzinga.com/markets/wiim/19/06/13859934/shares-of-several-healthcare-companies-are-trading-higher-with-the-overall-us-market-recent-comments | Benzinga Newsdesk | 2019-06-04T00:00:00 | ZTS |
1,412,165 | Jim Cramer Gives His Opinion On Wendy's, Exelon And More | https://www.benzinga.com/media/19/06/13855302/jim-cramer-gives-his-opinion-on-wendys-exelon-and-more | Craig Jones | 2019-06-04T00:00:00 | ZTS |
1,412,166 | BMO Capital Maintains Market Perform on Zoetis Inc. Class A Common Stock, Raises Price Target to $105 | https://www.benzinga.com/news/19/05/13704447/bmo-capital-maintains-market-perform-on-zoetis-inc-class-a-common-stock-raises-price-target-to-105 | Vick Meyer | 2019-05-09T00:00:00 | ZTS |
1,412,167 | Jim Cramer Shares His Thoughts On Cirrus Logic, Chart Industries And More | https://www.benzinga.com/media/19/05/13660545/jim-cramer-shares-his-thoughts-on-cirrus-logic-chart-industries-and-more | Craig Jones | 2019-05-03T00:00:00 | ZTS |
1,412,168 | Gabelli & Co. Downgrades Zoetis Inc. Class A Common Stock to Hold | https://www.benzinga.com/news/19/05/13661066/gabelli-co-downgrades-zoetis-inc-class-a-common-stock-to-hold | Vick Meyer | 2019-05-03T00:00:00 | ZTS |
1,412,169 | Zoetis Sees FY19 Adj. EPS $3.42-$3.52 vs $3.47 Est., Sales $6.10B-$6.225B | https://www.benzinga.com/news/19/05/13650230/zoetis-sees-fy19-adj-eps-3-42-3-52-vs-3-47-est-sales-6-10b-6-225b | Benzinga Newsdesk | 2019-05-02T00:00:00 | ZTS |
1,412,170 | Zoetis Q1 Adj. EPS $0.88 Beats $0.79 Estimate, Sales $1.455B Beat $1.45B Estimate | https://www.benzinga.com/news/earnings/19/05/13650221/zoetis-q1-adj-eps-0-88-beats-0-79-estimate-sales-1-455b-beat-1-45b-estimate | Benzinga Newsdesk | 2019-05-02T00:00:00 | ZTS |
1,412,171 | Earnings Scheduled For May 2, 2019 | https://www.benzinga.com/news/earnings/19/05/13648816/earnings-scheduled-for-may-2-2019 | Lisa Levin | 2019-05-02T00:00:00 | ZTS |
1,412,172 | The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut | https://www.benzinga.com/general/biotech/19/04/13484602/the-daily-biotech-pulse-recro-restructures-biotechs-raise-proceeds-in-droves-silk-road-ngm-biopha | Shanthi Rexaline | 2019-04-04T00:00:00 | ZTS |
1,412,173 | Credit Suisse Maintains Outperform on Zoetis, Raises Price Target to $112 | https://www.benzinga.com/news/19/04/13468095/credit-suisse-maintains-outperform-on-zoetis-raises-price-target-to-112 | Vick Meyer | 2019-04-02T00:00:00 | ZTS |
1,412,174 | The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial | https://www.benzinga.com/general/biotech/19/04/13466474/the-daily-biotech-pulse-fda-nod-for-adma-regulatory-setback-for-apyx- | Shanthi Rexaline | 2019-04-02T00:00:00 | ZTS |
1,412,175 | Barron's Picks And Pans: DowDuPont, Wells Fargo, Zoetis And More | https://www.benzinga.com/markets/cryptocurrency/19/03/13455075/barrons-picks-and-pans-dowdupont-wells-fargo-zoetis-and-more | Nelson Hem | 2019-03-30T00:00:00 | ZTS |
1,412,176 | The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback | https://www.benzinga.com/general/biotech/19/03/13406921/the-daily-biotech-pulse-immutep-gets-us-patent-conatus-nash-disappoin | Shanthi Rexaline | 2019-03-22T00:00:00 | ZTS |
1,412,177 | The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering | https://www.benzinga.com/general/biotech/19/03/13400097/the-daily-biotech-pulse-biogen-plummets-fda-greenlights-sleep-disorde | Shanthi Rexaline | 2019-03-21T00:00:00 | ZTS |
1,412,178 | The Daily Biotech Pulse: FDA Nod For Sage's Postpartum Depression Drug, Pfizer Invests In Gene Therapy Company | https://www.benzinga.com/general/biotech/19/03/13393022/the-daily-biotech-pulse-fda-nod-for-sages-postpartum-depression-drug- | Shanthi Rexaline | 2019-03-20T00:00:00 | ZTS |
1,412,179 | SunTrust Robinson Humphrey Initiates Coverage On Zoetis with Hold Rating, Announces $100 Price Target | https://www.benzinga.com/news/19/03/13392989/suntrust-robinson-humphrey-initiates-coverage-on-zoetis-with-hold-rating-announc | Vick Meyer | 2019-03-20T00:00:00 | ZTS |
1,412,180 | The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings | https://www.benzinga.com/general/biotech/19/03/13296855/the-daily-biotech-pulse-novartis-psoriasis-drug-found-superior-ascend | Shanthi Rexaline | 2019-03-05T00:00:00 | ZTS |
1,412,181 | Benzinga's Top Upgrades, Downgrades For March 4, 2019 | https://www.benzinga.com/analyst-ratings/upgrades/19/03/13289265/benzingas-top-upgrades-downgrades-for-march-4-2019 | Lisa Levin | 2019-03-04T00:00:00 | ZTS |
1,412,182 | Stifel Nicolaus Upgrades Zoetis to Buy | https://www.benzinga.com/news/19/03/13287708/stifel-nicolaus-upgrades-zoetis-to-buy | Benzinga_Newsdesk | 2019-03-04T00:00:00 | ZTS |
1,412,183 | BMO Capital Maintains Market Perform on Zoetis, Raises Price Target to $101 | https://www.benzinga.com/news/19/02/13236527/bmo-capital-maintains-market-perform-on-zoetis-raises-price-target-to-101 | Vick Meyer | 2019-02-25T00:00:00 | ZTS |
1,412,184 | Zoetis shares are trading higher after the company reported Q4 EPS of $0.79, beating the $0.77 estimate, and sales of $1.6 billion, beating the $1.52 billion estimate; the company also issued FY19 EPS guidance inline with analyst estimates. | https://www.benzinga.com/markets/wiim/19/02/13175961/zoetis-shares-are-trading-higher-after-the-company-reported-q4-eps-of-0- | Benzinga Newsdesk | 2019-02-14T00:00:00 | ZTS |
1,412,185 | JANA 13F Shows Liquidated Stakes In GM, Zoetis | https://www.benzinga.com/news/19/02/13174176/jana-13f-shows-liquidated-stakes-in-gm-zoetis | Benzinga Newsdesk | 2019-02-14T00:00:00 | ZTS |
1,412,186 | The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial | https://www.benzinga.com/general/biotech/19/02/13169934/the-daily-biotech-pulse-vanda-q4-results-inovio-debt-offering-caladri | Shanthi Rexaline | 2019-02-14T00:00:00 | ZTS |
1,412,187 | Zoetis Sees FY19 Adj. EPS $3.42-$3.52 vs $3.45 Estimate, Sales $6.175B-$6.3B vs $6.23B Est. | https://www.benzinga.com/news/19/02/13171205/zoetis-sees-fy19-adj-eps-3-42-3-52-vs-3-45-estimate-sales-6-175b-6-3b-vs-6-23b-e | Benzinga Newsdesk | 2019-02-14T00:00:00 | ZTS |
1,412,188 | Zoetis Q4 EPS $0.79 Beats $0.77 Estimate, Sales $1.6B Beat $1.52B Estimate | https://www.benzinga.com/news/earnings/19/02/13171200/zoetis-q4-eps-0-79-beats-0-77-estimate-sales-1-6b-beat-1-52b-estimate | Benzinga Newsdesk | 2019-02-14T00:00:00 | ZTS |
1,412,189 | Earnings Scheduled For February 14, 2019 | https://www.benzinga.com/news/earnings/19/02/13170209/earnings-scheduled-for-february-14-2019 | Lisa Levin | 2019-02-14T00:00:00 | ZTS |
1,412,190 | Zoetis Q4 Earnings Preview | https://www.benzinga.com/news/earnings-previews/19/02/13164067/a-look-at-zoetiss-earnings | Benzinga Newsdesk | 2019-02-13T00:00:00 | ZTS |
1,412,191 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials | https://www.benzinga.com/general/biotech/19/02/13113062/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trials | Shanthi Rexaline | 2019-02-10T00:00:00 | ZTS |
1,412,192 | UBS Initiates Coverage On Zoetis with Neutral Rating | https://www.benzinga.com/news/19/01/13023080/ubs-initiates-coverage-on-zoetis-with-neutral-rating | Benzinga_Newsdesk | 2019-01-23T00:00:00 | ZTS |
1,412,193 | The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen | https://www.benzinga.com/general/biotech/18/12/12843330/the-daily-biotech-pulse-vivus-extends-supply-deal-with-sandoz-applied | Shanthi Rexaline | 2018-12-13T00:00:00 | ZTS |
1,412,194 | Zoetis Raises Quarterly Dividend From $0.126 To $0.146/Share | https://www.benzinga.com/news/18/12/12841467/zoetis-raises-quarterly-dividend-from-0-126-to-0-146share | Benzinga Newsdesk | 2018-12-12T00:00:00 | ZTS |
1,412,195 | Zoetis Reports $2B Buyback | https://www.benzinga.com/news/18/12/12841430/zoetis-reports-2b-buyback | Benzinga Newsdesk | 2018-12-12T00:00:00 | ZTS |
1,412,196 | Stocks Trading Ex Dividend For Mon., Nov. 19, 2018 | https://www.benzinga.com/news/18/11/12724001/stocks-trading-ex-dividend-for-mon-nov-19-2018 | Benzinga Newsdesk | 2018-11-19T00:00:00 | ZTS |
1,412,197 | Stocks That Will Trade Ex Dividend Mon., Nov. 19, 2018 | https://www.benzinga.com/news/18/11/12716521/stocks-that-will-trade-ex-dividend-mon-nov-19-2018 | Benzinga Newsdesk | 2018-11-16T00:00:00 | ZTS |
1,412,198 | 13F From JANA Shows New 32K Share Stake In Zoetis | https://www.benzinga.com/news/18/11/12696900/13f-from-jana-shows-new-32k-share-stake-in-zoetis | Benzinga Newsdesk | 2018-11-14T00:00:00 | ZTS |
1,412,199 | Paws Up: The First Pets ETF Is Here | https://www.benzinga.com/trading-ideas/long-ideas/18/11/12646607/paws-up-the-first-pets-etf-is-here | ETF Professor | 2018-11-07T00:00:00 | ZTS |
1,412,200 | The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug | https://www.benzinga.com/general/biotech/18/11/12619845/the-daily-biotech-pulse-illumina-snaps-up-pacific-bioscience-thumbs-d | Shanthi Rexaline | 2018-11-02T00:00:00 | ZTS |
1,412,201 | Zoetis Raises FY18 Adj. EPS Guidance From $3-$3.10 To $3.08-$3.13 vs $3.07 Estimate | https://www.benzinga.com/news/18/11/12609607/zoetis-raises-fy18-adj-eps-guidance-from-3-3-10-to-3-08-3-13-vs-3-07-estimate | Benzinga Newsdesk | 2018-11-01T00:00:00 | ZTS |
1,412,202 | Zoetis Q3 EPS $0.83 Beats $0.77 Estimate, Sales $1.48B Beat $1.45B Estimate | https://www.benzinga.com/news/earnings/18/11/12609589/zoetis-q3-eps-0-83-beats-0-77-estimate-sales-1-48b-beat-1-45b-estimate | Benzinga Newsdesk | 2018-11-01T00:00:00 | ZTS |
1,412,203 | Earnings Scheduled For November 1, 2018 | https://www.benzinga.com/news/earnings/18/11/12608552/earnings-scheduled-for-november-1-2018 | Lisa Levin | 2018-11-01T00:00:00 | ZTS |
1,412,204 | JP Morgan Upgrades Zoetis to Overweight, Raises Price Target to $100 | https://www.benzinga.com/news/18/10/12504291/jp-morgan-upgrades-zoetis-to-overweight-raises-price-target-to-100 | Benzinga Newsdesk | 2018-10-15T00:00:00 | ZTS |
1,412,205 | Stocks Which Set New 52-Week High Yesterday, October 3rd | https://www.benzinga.com/trading-ideas/technicals/18/10/12459146/stocks-which-set-new-52-week-high-yesterday-october-3rd | Benzinga Newsdesk | 2018-10-04T00:00:00 | ZTS |
1,412,206 | Stifel Drops Bullish Zoetis Thesis After 108% Outperformance | https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12243048/stifel-drops-bullish-zoetis-thesis-after-108-outperform | Jayson Derrick | 2018-08-22T00:00:00 | ZTS |
1,412,207 | Benzinga's Top Upgrades, Downgrades For August 22, 2018 | https://www.benzinga.com/analyst-ratings/upgrades/18/08/12243722/benzingas-top-upgrades-downgrades-for-august-22-2018 | Lisa Levin | 2018-08-22T00:00:00 | ZTS |
1,412,208 | Stifel Nicolaus Downgrades Zoetis to Hold | https://www.benzinga.com/news/18/08/12242613/stifel-nicolaus-downgrades-zoetis-to-hold | Benzinga_Newsdesk | 2018-08-22T00:00:00 | ZTS |
1,412,209 | 10 Biggest Price Target Changes For Tuesday | https://www.benzinga.com/analyst-ratings/price-target/18/08/12200458/10-biggest-price-target-changes-for-tuesday | Lisa Levin | 2018-08-14T00:00:00 | ZTS |
1,412,210 | Argus Maintains Buy on Zoetis, Raises Price Target to $103 | https://www.benzinga.com/news/18/08/12198313/argus-maintains-buy-on-zoetis-raises-price-target-to-103 | Vick Meyer | 2018-08-14T00:00:00 | ZTS |
1,412,211 | Stocks Which Set New 52-Week High Yesterday, August 9th | https://www.benzinga.com/trading-ideas/technicals/18/08/12183457/stocks-which-set-new-52-week-high-yesterday-august-9th | Benzinga Newsdesk | 2018-08-10T00:00:00 | ZTS |
1,412,212 | Stocks That Made New 52-Week Highs So Far Today Include: Nike, Becton, Cintas, Exelon, Amazon, United Continental, Michael Kors, Target, Medtronic, W.W. Grainger, Ross Stores, Zoetis, Robert Half, IHS Markit, VF, Flowserv, Verisk Analytics, aApple | https://www.benzinga.com/trading-ideas/technicals/18/08/12175468/stocks-that-made-new-52-week-highs-so-far-today-include-nike | Benzinga Newsdesk | 2018-08-09T00:00:00 | ZTS |
1,412,213 | Stocks Which Set New 52-Week High Yesterday, August 8th | https://www.benzinga.com/trading-ideas/technicals/18/08/12175384/stocks-which-set-new-52-week-high-yesterday-august-8th | Benzinga Newsdesk | 2018-08-09T00:00:00 | ZTS |
1,412,214 | The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings | https://www.benzinga.com/general/biotech/18/08/12172009/the-daily-biotech-pulse-ampio-slides-on-offering-sangamos-positive-tr | Shanthi Rexaline | 2018-08-09T00:00:00 | ZTS |
1,412,215 | Stocks That Made New 52-Week Highs So Far Today Include: Medtronic, Amazon, Pfizer, AES, W.W. Grainger, Centene, Chipotle, Emerson Electric, Zoetis, Michael Kors, United Continental, VF, Aetna, Ross Stores, and UnitedHealth Group | https://www.benzinga.com/trading-ideas/technicals/18/08/12166091/stocks-that-made-new-52-week-highs-so-far-today-include-medt | Benzinga Newsdesk | 2018-08-08T00:00:00 | ZTS |
1,412,216 | Stocks Which Set New 52-Week High Yesterday, August 7th | https://www.benzinga.com/trading-ideas/technicals/18/08/12165578/stocks-which-set-new-52-week-high-yesterday-august-7th | Benzinga Newsdesk | 2018-08-08T00:00:00 | ZTS |
1,412,217 | The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict | https://www.benzinga.com/general/biotech/18/08/12162539/the-daily-biotech-pulse-fda-panel-backs-insmed-eidos-maiden-earnings- | Shanthi Rexaline | 2018-08-08T00:00:00 | ZTS |
1,412,218 | Stocks That Made New 52-Week Highs Earlier Today Include: SL Green Realty, Verisk Analytics, Medtronics, Pfizer, Conoco Phillips, Archer-Daniels, Eli Lilly, Merck, Phillips 66, Costco, Advance Auto Parts, Norfolk Southern, CSX, Zoetis, Apple, and Disney | https://www.benzinga.com/trading-ideas/technicals/18/08/12155877/stocks-that-made-new-52-week-highs-earlier-today-include-sl- | Benzinga Newsdesk | 2018-08-07T00:00:00 | ZTS |
1,412,219 | Stocks Which Set New 52-Week High Yesterday, August 6th | https://www.benzinga.com/trading-ideas/small-cap-analysis/18/08/12155686/stocks-which-set-new-52-week-high-yesterday-august-6 | Benzinga Newsdesk | 2018-08-07T00:00:00 | ZTS |
1,412,220 | Stocks Which Set New 52-Week Highs Friday, August 3rd | https://www.benzinga.com/trading-ideas/technicals/18/08/12147637/stocks-which-set-new-52-week-highs-friday-august-3rd | Benzinga Newsdesk | 2018-08-06T00:00:00 | ZTS |